Concise Prescribing Info
Dosage/Direction for Use
Adult : IV/SC Diagnosis of hypothalamic-pituitary-gonadal dysfunction 100 mcg as a single dose, given early in the follicular stage of the menstrual cycle (day 1-7). Primary hypothalamic amenorrhoea Intermittent pulse pump providing 5-20 mcg every 90 mins for up to 6 mth or until conception.
Dosage Details
Diagnosis of hypothalamic-pituitary-gonadal dysfunction
Adult: 100 mcg as a single dose by IV or SC inj. In females, it should be given early in the follicular stage of the menstrual cycle (day 1-7).
Child: >1 yr: 2.5 mcg/kg as a single dose. Max: 100 mcg/dose.

Primary hypothalamic amenorrhoea
Adult: Intermittent pulse pump providing 5-20 mcg over 1 minute every 90 minutes for up to 6 mth or until conception. Dose may be administered via IV or SC route.
Pituitary adenoma; weight-related amenorrhoea; pregnancy.
Special Precautions
Women with polycystic ovary disease or endometriotic cysts. May also increase cervical resistance thus making it difficult to dilate the cervix for intra-uterine procedures. Monitor men at risk of tumor flare. Pituitary adenoma.
Adverse Reactions
GI disturbances; headache, lightheadedness, increase in menstrual bleeding; paradoxical suppression of the pituitary gonadal axis; hot flushes and sexual dysfunction in men; vaginal dryness, hot flushes, loss of libido in premenopausal women; osteoporosis if sufficiently prolonged; ovarian hyperstimulation; Inj site reactions/pain; tumor flare (may manifest as increase in bone pain); effects related to changes in the hormonal milieu.
Drug Interactions
Spironolactone and levodopa can stimulate gonadotrophins while phenothiazines and dopamine antagonists can inhibit gonadotrophin secretion. Corticosteroids and drugs affecting pituitary secretion of gonadotrophins may also affect efficacy of the drug.
Lab Interference
Alterations in liver function tests and blood lipids.
Description: Gonadorelin, a synthetic form of hypothalamic gonadotrophin-releasing hormone stimulates the synthesis and release of follicle-stimulating hormone and luteinizing hormone.
Disclaimer: This information is independently developed by MIMS based on Gonadorelin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in